Zenas BioPharma, Inc. Common Stock (ZBIO) — Financial Flexibility Index
Zenas BioPharma, Inc. Common Stock (ZBIO) has a Financial Flexibility Index of -0.06x as of June 2026. Free cash flow of $-27.24 Million (operating CF $-57.24 Million minus capex $30.00 Million) represents 0% of total liabilities ($454.59 Million). Check Zenas BioPharma, Inc. Common Stock (ZBIO) total reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Zenas BioPharma, Inc. Common Stock Financial Flexibility Index (2022–2025)
Historical Financial Flexibility Index trend for Zenas BioPharma, Inc. Common Stock across 4 annual periods. For the full cash flow conversion analysis, see how efficiently does Zenas BioPharma, Inc. Common Stock generate cash.
Annual Financial Flexibility Index for Zenas BioPharma, Inc. Common Stock (2022–2025)
Year-by-year free cash flow to debt coverage for Zenas BioPharma, Inc. Common Stock. Explore ZBIO debt coverage from operations to assess how comfortably operating cash covers total debt obligations.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -1.22x | $-172.31 Million | $-172.33 Million | $141.50 Million | ▲ +41.4% |
| 2024 | -2.08x | $-119.54 Million | $-119.67 Million | $57.51 Million | ▼ -1902.2% |
| 2023 | -0.10x | $-30.51 Million | $-30.53 Million | $293.90 Million | ▲ +56.3% |
| 2022 | -0.24x | $-63.45 Million | $-65.65 Million | $266.87 Million | — |